Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products
Lyndra, Inc. (Lyndra) announced today a partnership with Allergan plc to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease. The basis of the collaboration between the Boston-based startup and Allergan is Lyndra’s innovative sustained-release technology, which has the potential to transform drugs typically dosed daily to once-weekly oral dosing.
Printed from https://innovationblog.partners.org/lyndra-inc-allergan-sign-partnership-develop-ultra-long-acting-oral-products · Published 07 Nov 2018
© Mass General Brigham Incorporated. All rights reserved.